王江友,苏晞

• 1:武汉亚洲心脏病医院心内科

摘要(Abstract)：

<正>双联抗血小板治疗(DAPT)策略是基于阿司匹林基础上加用一种血小板P2Y12抑制剂(如噻吩并吡啶类药物:氯吡格雷或普拉格雷;环戊基三唑嘧啶类药物:替格瑞洛),用于减少冠状动脉支架置入后支架内血栓形成(stent thrombosis,ST)的风险和预防非支架置入血管冠状动脉事件的发生。DAPT策略在减少临床缺血事件中取得成功,但延长DAPT时限将会增加出血并发症的发生风险,如何平衡DAPT的有效性与安全性是值得关注的问题。目前,开展的大量研究旨

关键词(KeyWords)： 经皮冠状动脉介入治疗;双联抗血小板治疗;时限;选择

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王江友,苏晞

参考文献(References)：

• [1]CAPRIE Steering Committee.Arandomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).Lancet,1996,348(9038):1329-1339.
• [2]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345(7):494-502.
• [3]Yusuf S,Mehta SR,Zhao F,et al.Early and late effects of clopidogrel in patients with acute coronary syndromes.Circulation,2003,107(7):966-972.
• [4]Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study.Lancet,2001,358(9281):527-533.
• [5]Steinhubl SR,Berger PB,Mann JT 3rd,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial.JAMA,2002,288(19):2411-2420.
• [6]Hamm CW,Bertrand M,Braunwald E.Acute coronary syndrome without ST elevation:implementation of new guidelines.Lancet,2001,358(9292):1533-1538.
• [7]Pfisterer M,Brunner-La Rocca HP,Buser PT,et al.Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drugeluting versus bare-metal stents.J Am Coll Cardiol,2006,48(12):2584-2591.
• [8]U.S.Food&Drug Administration.Summaryminutes:meeting of the circulatory system devicespanel.Available at:http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4253m1-Final1207 summ.pdf.2006.
• [9]Wiviott SD,Braunwald E,Mc Cabe CH,et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial:a subanalysis of a randomised trial.Lancet,2008,371(9621):1353-1363.
• [10]Nakazawa G,Finn AV,Joner M,et al.Delayed arterial healing and increased late stent thrombosis at culprit sites after drugeluting stent placement for acute myocardial infarction patients:an autopsy study.Circulation,2008,118(11):1138-1145.
• [11]Pfisterer ME.Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction:a new red flag is raised.Circulation,2008,118(11):1117-1119.
• [12]Berger PB,Bhatt DL,Fuster V,et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease:results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,Management,and Avoidance(CHARISMA)trial.Circulation,2010,121(23):2575-2583.
• [13]Bhatt DL,Fox KA,Hacke W,et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.N Engl J Med,2006,354(16):1706-1717.
• [14]Bowry AD,Brookhart MA,Choudhry NK.Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.Am J Cardiol,2008,101(7):960-966.
• [15]Morrow DA,Braunwald E,Bonaca MP,et al.Vorapaxar in the secondary prevention of atherothrombotic events.N Engl J Med,2012,366(15):1404-1413.
• [16]Baber U,Mehran R,Sharma SK,et al.Impact of the everolimuseluting stent on stent thrombosis:a meta-analysis of 13randomized trials.J Am Coll Cardiol,2011,58(15):1569-1577.
• [17]Palmerini T,Biondi-Zoccai G,Della Riva D,et al.Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis.Lancet,2012,379(9824):1393-1402.
• [18]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol,2011,58(24):e44-e122.
• [19]Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC Guideline for the Management of Patients with Non-STElevation Acute Coronary Syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2014,64(24):e139-e228.
• [20]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [21]Roffi M,Patrono C,Collet JP,et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC).Eur Heart J,2016,37(3):267-315.
• [22]韩雅玲.中国经皮冠状动脉介入治疗指南2012(简本).中华心血管病杂志,2012,40(3):18-26.
• [23]Gwon HC,Hahn JY,Park KW,et al.Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting(EXCELLENT)randomized,multicenter study.Circulation,2012,125(3):505-513.
• [24]Marco B,Gianluca C,Monia M,et al.Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial.Circulation,2012,125(16):2015-2026.
• [25]Kim BK,Hong MK,Shin DH,et al.A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial(REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).J Am Coll Cardiol,2012,60(15):1340-1348.
• [26]Feres F,Costa RA,Abizaid A,et al.Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial.JAMA,2013,310(23):2510-2522.
• [27]Colombo A,Chieffo A,Frasheri A,et al.Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial.J Am Coll Cardiol,2014,64(20):2086-2097.
• [28]Gilard M,Barragan P,Noryani AA,et al.6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin:the randomized,multicenter ITALIC trial.J Am Coll Cardiol,2015,65(8):777-786.
• [29]Schulz-Schüpke S,Byrne RA,Ten Berg JM,et al.ISAR-SAFE:a randomized,double-blind,placebo-controlled trial of 6 vs.12months of clopidogrel therapy after drug-eluting stenting.Eur Heart J,2015,36(20):1252-1263.
• [30]Campo G,Tebaldi M,Vranckx P,et al.Short-versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis:a PRODIGY trial substudy(Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).J Am Coll Cardiol,2014,63(6):506-512.
• [31]Giustino G,Baber U,Sartori S,et al.Duration of dual antiplatelet therapy after drug-eluting stent implantation:a systematic review and meta-analysis of randomized controlled trials.J Am Coll Cardiol,2015,65(13):1298-1310.
• [32]Palmerini T,Benedetto U,Bacchi-Reggiani L,et al.Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation:a pairwise and Bayesian network meta-analysis of randomised trials.Lancet,2015,385(9985):2371-2382.
• [33]Claessen BE,Henriques JP,Jaffer FA,et al.Stent thrombosis:a clinical perspective.JACC Cardiovasc Interv,2014,7(10):1081-1092.
• [34]Stefanini GG,Byrne RA,Serruys PW,et al.Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at4 years in patients undergoing percutaneous coronary intervention:a pooled analysis of individual patient data from the ISAR-TEST 3,ISAR-TEST 4,and LEADERS randomized trials.Eur Heart J,2012,33(10):1214-1222.
• [35]Camenzind E,Boersma E,Wijns W,et al.Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.Eur Heart J,2014,35(29):1932-1948.
• [36]Lee CW,Ahn JM,Park DW,et al.Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation:a randomized,controlled trial.Circulation,2014,129(3):304-312.
• [37]Park SJ,Park DW,Kim YH,et al.Duration of dual antiplatelet therapy after implantation of drug-eluting stents.N Engl J Med,2010,362(15):1374-1382.
• [38]Collet JP,Cuisset T,RangéG,et al.Bedside monitoring to adjust antiplatelet therapy for coronary stenting.N Engl J Med,2012,367(22):2100-2109.
• [39]Collet JP,Silvain J,Barthélémy O,et al.Dual-antiplatelet treatmentbeyond 1 year after drug-eluting stent implantation(ARCTIC-Interruption):a randomizedtrial.Lancet,2014,384(9954):1577-1585.
• [40]崔炜.解读最新证据:再议双联抗血小板治疗持续时间问题.中国介入心脏病学杂志,2015,23(3):173-176.
• [41]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [42]Elmariah S,Mauri L,Doros G,et al.Extended duration dual antiplatelet therapy and mortality:a systematic review and metaanalysis.Lancet,2015,385(9970):792-798.
• [43]Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med,2015,372(19):1791-1800.
• [44]Levine GN,Jeong YH,Goto S,et al.Expert consensus document:World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.Nat Rev Cardiol,2014,11(10):597-606.
• [45]van Werkum JW,Heestermans AA,Zomer AC,et al.Predictors of coronary stent thrombosis:the Dutch Stent Thrombosis Registry.J Am Coll Cardiol,2009,53(16):1399-1409.
• [46]Montalescot G,Brieger D,Dalby AJ,et al.Duration of Dual Antiplatelet Therapy After Coronary Stenting:A Review of the Evidence.J Am Coll Cardiol,2015,66(7):832-847.